K.M. Bell-McGuinn

498 total citations
10 papers, 219 citations indexed

About

K.M. Bell-McGuinn is a scholar working on Oncology, Surgery and Reproductive Medicine. According to data from OpenAlex, K.M. Bell-McGuinn has authored 10 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Surgery and 4 papers in Reproductive Medicine. Recurrent topics in K.M. Bell-McGuinn's work include Ovarian cancer diagnosis and treatment (4 papers), PARP inhibition in cancer therapy (4 papers) and BRCA gene mutations in cancer (3 papers). K.M. Bell-McGuinn is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), PARP inhibition in cancer therapy (4 papers) and BRCA gene mutations in cancer (3 papers). K.M. Bell-McGuinn collaborates with scholars based in United States, United Kingdom and Spain. K.M. Bell-McGuinn's co-authors include Jason Konner, David R. Spriggs, Carol Aghajanian, Paul Sabbatini, M. William Audeh, Noah D. Kauff, Andrew Tutt, J. Carmichael, Kenneth Offit and R.R. Barakat and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

K.M. Bell-McGuinn

9 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.M. Bell-McGuinn United States 5 152 113 81 76 36 10 219
Paulo Mora United States 5 203 1.3× 137 1.2× 73 0.9× 43 0.6× 22 0.6× 6 251
Philip Rowe United Kingdom 6 328 2.2× 201 1.8× 152 1.9× 112 1.5× 44 1.2× 7 389
Pat Glenn United States 2 198 1.3× 152 1.3× 137 1.7× 153 2.0× 54 1.5× 2 291
Valerie Bowering Canada 10 310 2.0× 176 1.6× 168 2.1× 59 0.8× 37 1.0× 28 378
C. Whalen United States 5 163 1.1× 149 1.3× 106 1.3× 28 0.4× 16 0.4× 13 233
Jennifer Alsop United Kingdom 3 72 0.5× 66 0.6× 52 0.6× 63 0.8× 36 1.0× 3 178
Yannick Boursin France 6 69 0.5× 75 0.7× 75 0.9× 38 0.5× 67 1.9× 9 190
Marthe M. de Jonge Netherlands 8 133 0.9× 171 1.5× 111 1.4× 109 1.4× 63 1.8× 8 307
David Huntsman Canada 2 57 0.4× 136 1.2× 66 0.8× 23 0.3× 72 2.0× 3 216
Jeff Isaacson United States 5 258 1.7× 99 0.9× 116 1.4× 44 0.6× 21 0.6× 8 284

Countries citing papers authored by K.M. Bell-McGuinn

Since Specialization
Citations

This map shows the geographic impact of K.M. Bell-McGuinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.M. Bell-McGuinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.M. Bell-McGuinn more than expected).

Fields of papers citing papers by K.M. Bell-McGuinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.M. Bell-McGuinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.M. Bell-McGuinn. The network helps show where K.M. Bell-McGuinn may publish in the future.

Co-authorship network of co-authors of K.M. Bell-McGuinn

This figure shows the co-authorship network connecting the top 25 collaborators of K.M. Bell-McGuinn. A scholar is included among the top collaborators of K.M. Bell-McGuinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.M. Bell-McGuinn. K.M. Bell-McGuinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Powles, Thomas, Daniel P. Petrylak, Ronald de Wit, et al.. (2019). Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. Annals of Oncology. 30. v373–v374. 1 indexed citations
2.
Petrylak, Daniel P., Cora N. Sternberg, Alexandra Drakaki, et al.. (2018). RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Annals of Oncology. 29. viii304–viii305. 1 indexed citations
3.
Petrylak, Daniel P., K.N. Chi, Alexandra Drakaki, et al.. (2017). RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology. 28. v621–v621. 4 indexed citations
4.
5.
6.
Bell-McGuinn, K.M., Jason Konner, William P. Tew, & David R. Spriggs. (2011). New drugs for ovarian cancer. Annals of Oncology. 22. viii77–viii82. 10 indexed citations
7.
Gallagher, David, Jason Konner, K.M. Bell-McGuinn, et al.. (2010). Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Annals of Oncology. 22(5). 1127–1132. 91 indexed citations
8.
Sabbatini, Paul, David R. Spriggs, Carol Aghajanian, et al.. (2009). Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecologic Oncology. 116(1). 66–71. 7 indexed citations
9.
Audeh, M. William, Michael Friedländer, K.M. Bell-McGuinn, et al.. (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. Journal of Clinical Oncology. 27(15_suppl). 5500–5500. 82 indexed citations
10.
Matthews, Carolyn M., Minal Barve, K.M. Bell-McGuinn, et al.. (2008). 519 POSTER A phase 2, single-arm study of volociximab (an anti-a5b1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer. European Journal of Cancer Supplements. 6(12). 164–165. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paulo Mora Breakdown of academic impact, for papers by Philip Rowe Breakdown of academic impact, for papers by Pat Glenn Breakdown of academic impact, for papers by Valerie Bowering Breakdown of academic impact, for papers by C. Whalen Breakdown of academic impact, for papers by Jennifer Alsop Breakdown of academic impact, for papers by Yannick Boursin Breakdown of academic impact, for papers by Marthe M. de Jonge Breakdown of academic impact, for papers by David Huntsman Breakdown of academic impact, for papers by Jeff Isaacson
Rankless by CCL
2026